Screening for BRCA genes and prostate cancer
The BRCA gene mutation (source), long known for their correlation with aggressive forms of breast and ovarian cancer, are also linked to the development of aggressive forms of prostate cancer.
In light of this evidence, it is being discussed whether screening for prostate cancer in individuals with a BRCA gene mutation might be a good strategy to detect and thus treat the disease early.
Current screening for prostate cancer with the prostate-specific antigen test (PSA) has been criticised in recent years for its poor ability to distinguish a healthy man from a patient with cancer.
This is mainly due to the fact that high-grade prostate tumours can lose PSA expression, rather than increase it, generating what is called the “paradox” of the PSA test.
The measurement of PSA in blood has shown that it cannot be used as a screening test in the general population.
However, the question is being raised as to whether in selected subgroups of individuals with certain risk factors it may help to identify the onset of prostate cancer at an early stage.
Prostate cancer seems to be more frequent in people who have had other cases of the disease in their family. Having a father, brother or uncle with prostate cancer doubles the risk of developing this disease in a man, suggesting that in some cases there may be a hereditary or genetic factor.
Could PSA measurement be indicated for these genetically defined groups? New research seems to suggest yes!
A team of scientists worldwide recently published the results of a study on PSA screening in men with mutations in the BRCA1 and BRCA2 genes (source).
The same genes known to increase the likelihood of breast and ovarian cancer in women are also risk factors for aggressive prostate cancer in men. It has been seen that cells with defective BRCA genes have an impaired ability to repair DNA damage that, once accumulated, transforms the cell into cancer.
What the researchers wanted to show was whether PSA screening could help detect prostate cancer in men who test positive for BRCA mutations compared to those without mutations. About 2,900 men aged 45-69 years were recruited and divided into four groups: one group positive for the BRCA1 mutation, one group positive for the BRCA2 mutation, and two groups negative for mutations in both genes. The men were screened annually for four years and underwent prostate biopsy if their PSA levels were above 3.0 nanograms per decilitre of blood.
A total of 357 men underwent biopsy and 112 of them were diagnosed with prostate cancer. Carriers of the BRCA2 mutation had the highest risk of cancer: 5.2% of them had been diagnosed with the disease and most of their tumours had intermediate or high risk of progression. BRCA1 mutation carriers had a lower risk: 3.4% of them had been diagnosed with prostate cancer. And men who tested negative for the BRCA1 and BRCA2 mutations had the lowest risk overall, with diagnosis rates of 3.0% and 2.7%, respectively.
Based on the results, it was proposed to the regulatory bodies to update the guidelines so that men with BRCA2 defects can undergo regular PSA screening after the age of 40.
Based on the observed results, it would seem that men should consider testing for BRCA mutations under the following conditions:
- If there is a history of prostate, breast or ovarian cancer in close relatives, particularly among younger members
- if other family members test positive for BRCA1 or BRCA2 mutations
- if they are of Ashkenazi Jewish origin, as BRCA mutations frequently occur in this ethnic population.

NIB biotec
NIB biotec
NIB biotec
Leave a Comment
Want to join the discussion?Sentitevi liberi di contribuire!